secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2024-07-18T23:59:59+00:00
Accession:  0001493152-24-028363
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics appoints Dr. Srini Tenjarla as SVP of CMC and Formulation
-----------------------------------------------------------------------------

- Tenjarla joins from Takeda, where he was VP and Head of Drug Product Development.
- At Takeda he oversaw phase-appropriate development from Phase 1 through validation.
- Previously held leadership roles at Shire, including VP of Pharmaceutical Sciences.
- He holds a Ph.D. in Pharmaceutical Sciences from the University of Houston.
- Appointment effective July 15, 2024; will oversee CMC activities across pipeline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224028363/0001493152-24-028363-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000149315224028363/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-028363

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer